Reprogramming the Gut–Metabolic Axis: Microbiota Dynamics, Causal Mechanisms, and Therapeutic Prospects in Metabolic Disease

gut microbiota; metabolic dysfunction; obesity; type 2 diabetes; NAFLD; dysbiosis; short- chain fatty acids; bile acids; insulin resistance; intestinal permeability; inflammation; Akkermansia muciniphila; Faecalibacterium prausnitzii; GLP- 1 signaling; FXR; metabolic endotoxemia; microbiome therapeutics; precision medicine; host–microbe interaction; causal inference

1Mustayeva Guliston Buribaevna,
assistant, Department of Infection Diseases,
Samarkand, Uzbekistan. Samarkand State
Medical Universite.Guliston.
buriboуevna@gmail.com
ORCID ID: https://orcid.org/ 0009-00018702-7534

2Makhmud Dusmukhamedov,
DSc, professor of the pediatric surgical stomatology
Tashkent medical university.
mdusmukhamedov@gmail.com
https://orcid.org/my-orcid?orcid=0009-00026373-0943

3Dusmukhamedov Dilshod Makhmudjanovich,
DSc, professor of the department of pediatric
surgical stomatology. Tashkent medical
university.
Email: dr.ddusmuxamedov@gmail.com
https://orcid.org/0009-0009-3413-3817

4Rakhmatullaeva Makhfuza Mubinovna,
Doctor of Medical Sciences (DSc), Associate
Professor of the Department of Obstetrics and
Gynecology in Family Medicine, Bukhara
State Medical Institute named after Abu Ali
ibn Sina, Uzbekistan.
Email: rahmatullayeva.mahfuza@bsmi.uz
https://orcid.org/00000003-1987-6136

Received-17-05-2026
Revised-20-06-2026
Accepted-25-06-2026

European Journal of Prosthodontics and Restorative Dentistry (2026) 34(4S), 70–80

Reprogramming the Gut-Metabolic Axis: Microbiota Dynamics, Causal Mechanisms, and Therapeutic Prospects in Metabolic Disease

Background: The gut microbiota constitutes a metabolically active interface between diet, host physiology, and metabolic health. Growing evidence implicates microbial dysbiosis in the onset and progression of obesity, type 2 diabetes (T2D), and non- alcoholic fatty liver disease (NAFLD) through mechanisms that extend beyond mere association. Yet, defining causality within this intricate host–microbe network remains an unresolved frontier. Objective: This study critically examines causal pathways linking gut microbial alterations to metabolic dysfunction, synthesizing insights from experimental and translational research to identify mechanistic determinants and therapeutic leverage points within the gut–metabolic axis. Methods: A conceptual, evidence- based synthesis was conducted, integrating findings from longitudinal human cohorts, gnotobiotic and fecal microbiota transplantation models, and clinical interventional trials published between 2015 and 2025. Priority was given to studies employing causal inference frameworks, isotope- tracing metabolomics, and mechanistic mapping of microbial metabolites. Key Findings: Microbial communities influence glucose and lipid homeostasis through the modulation of bile acid pools, short- chain fatty acid (SCFA) production, and branched- chain amino acid metabolism. Loss of butyrate- producing genera (Faecalibacterium, Roseburia) and expansion of pathobionts disrupt epithelial integrity, fostering systemic inflammation and insulin resistance. Conversely, restoration of taxa such as Akkermansia muciniphila and engineered Bacteroides strains enhances mucosal signaling via GLP- 1 and FXR pathways, improving metabolic outcomes (Lynch & Pedersen, 2016; Thaiss et al., 2018). Conclusion: The gut microbiota operates as a causal modulator rather than a passive correlate of metabolic disease. Decoding its mechanistic influence unveils novel translational opportunities, from microbiota- targeted therapeutics to individualized metabolic interventions redefining chronic disease management.

•••••••••••••••••••••••••••••••• ejprd.org- Published by Riset Publishing Services LLC.

EJPRD

Copyright © 2026 by Riset Publishing Services LLC